Definiens has unveiled the latest version of its Tissuemap image analysis application.
Tissuemap 3.0 quantitatively assesses cellular structures and substructures in whole tissue sections and tissue microarrays, helping researchers discover, validate and measure new drug targets and disease specific biomarkers.
It accelerates image analysis by automatically identifying and quantifying nuclear, cytoplasmic and membrane markers in epithelial tumours and xenografts, providing researchers with fast, accurate and reproducible results.
The application can handle both whole section slides and tissue microarrays and can differentiate between viable and necrotic tissue in xenografts.
Implementing automated image analysis enables biotechnology and pharmaceutical companies to improve the prioritisation of quality drug candidates by identifying poor candidates earlier in the drug development process and thereby realise substantial cost savings.
Definiens Tissuemap 3.0 comes with a set of pre-defined tools to detect and quantify specific morphological or functional structures in tissues, such as tumour sections.
The application is built on Definiens XD, Definiens's multidimensional image analysis platform, which is highly flexible, scalable and supports a range of image acquisition devices.
